In this episode, editor in chief Joseph E. Safdieh, MD, FAAN, highlights articles about a promising blood test to distinguish Parkinson’s disease from dementia with Lewy bodies, how CAR T-cell therapies are showing potential for patients with glioblastoma, and a new wireless electroencephalogram device that can even monitor young children with epilepsy.

In this episode, editor in chief Joseph E. Safdieh, MD, FAAN, highlights articles about whether small fiber neuropathy is an autoimmune disorder; Merit Cudkowicz, MD, MSc, FAAN, recipient of this year’s AAN Lifetime Achievement Award for Clinically Relevant Research; and how neurologist couples pursue work-life balance.

In this episode, editor in chief Joseph E. Safdieh, MD, FAAN, highlights articles about eptinezumab, a treatment for episodic cluster headache; how positioning the head flat before a thrombectomy benefited patients with large vessel occlusion stroke; and what rural neurology looks like in 2025, the first story in our new series, Neurology in America.

In this episode, editor-in-chief Joseph E. Safdieh, MD, FAAN, highlights articles about upadacitinib, a new treatment for giant-cell arteritis; growing evidence linking oral health to a higher risk of neurologic conditions; and why a trial of a new meningitis B vaccine drew a mixed response.

In this episode, editor-in-chief Joseph E. Safdieh, MD, FAAN, highlights articles on the association of shortened telomeres on risk for stroke, late-life depression and dementia; affect of research funding cuts on tenure/promotion opportunities; and herpes zoster vaccine and reduced dementia risk.

In this episode, editor-in-chief Joseph E. Safdieh, MD, FAAN, highlights articles studies showing persistent fatigue after TIA, the neurologic complications of measles, and the impact of the dismantling of a CDC surveillance program of epilepsy.

In this episode, editor-in-chief Joseph E. Safdieh, MD, FAAN, highlights articles studies showing persistent fatigue after TIA, the neurologic complications of measles, and the impact of the dismantling of a CDC surveillance program of epilepsy.

In this episode, editor-in-chief Joseph E. Safdieh, MD, FAAN, highlights articles about early studies finding dopamine cellular therapies were safe and tolerable for patients with Parkinson’s, use of GLP-1 agonists were associated with reduced dementia risks, and the FDA use of accelerated approvals for several neurology drugs are under scrutiny.